Navigation Links
Researchers discover precisely how thalidomide causes birth defects
Date:4/19/2011

Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects. This is important as thalidomide is still used to treat diseases like multiple myeloma and leprosy, and is being tested for cancers and autoimmune disorders. This discovery was recently published online in the FASEB Journal (http://www.fasebj.org).

"The ability of thalidomide breakdown products to cause birth defects complicates our attempts to understand how the birth defects arise and the search for safer alternatives to thalidomide, although the rabbit embryo culture model will facilitate both processes," said Peter G. Wells, Pharm.D., a researcher involved in the work from the Department of Pharmacology and Toxicology at the University of Toronto in Ontario, Canada.

Specifically, Wells and colleagues found that birth defects result from not only thalidomide, but also from the compounds that it breaks down to in the body, which last up to 40 times longer in the body than thalidomide itself. These compounds ultimately lead to the production of highly toxic forms of oxygen, called "reactive oxygen species," (ROS) including hydrogen peroxide and free radicals that alter disrupt normal embryonic development, causing birth defects.

To make this discovery, the scientists developed a new animal model for fetal thalidomide exposure by extracting rabbit embryos from pregnant mothers during the first trimester of pregnancy, when the limbs and other structures are developing. Then they cultured the embryos in dishes for one to two days, with or without exposure to thalidomide or one of its breakdown products. Front and hind limb deformities as well as other abnormalities were observed only in the embryos exposed to thalidomide or one of its products. DNA damage caused by ROS and free radicals was similarly increased only in the exposed embryos.

"Administering thalidomide to pregnant women remains was of the biggest mistakes made in modern medicine," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal, "Yet we now use thalidomide and related products as effective therapies for serious diseases. This research not only explains what caused all that misery years ago, but promises to help us find safer alternatives to thalidomide in the future."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Researchers get a first look at the mechanics of membrane proteins
2. Jefferson researchers unlock key to personalized cancer medicine using tumor metabolism
3. NIH researchers complete whole-exome sequencing of skin cancer
4. New genetic tool helps researchers to analyze cells most important functions
5. NIH researchers identify cause and new treatment for common recurrent fever in children
6. UMMS researchers develop new technology to screen and analyze genetic mutations
7. Livermore researchers develop battery-less chemical detector
8. Researchers ID microbe responsible for methane from landfills
9. Researchers identify new role for cilia protein in mitosis
10. Researchers link herpes to Alzheimers disease
11. Researchers say children need horticultural interventions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated network ... two long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical ... Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will assume ...
(Date:2/10/2016)... ... 2016 , ... SonaCare Medical, LLC reports the introduction of ... monitoring. The inaugural launch of this new technology occurred over the course of ... to a HIFU technical expert at SonaCare Medical headquarters. , Sonalink allows ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate ... and Singapore in the latest adipose and bone marrow therapies. , Through ...
Breaking Biology Technology: